1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer.
(
- Contribution to journal › Article
- 2022
-
Mark
Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors
(
- Contribution to journal › Article